Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MMP-2/MMP-9-IN-1 是一种有效的、具有高选择性和可口服的 IV 型胶原酶 (MMP-9和MMP-2) 抑制剂,对 MMP-9 和 MMP-2具有抑制作用, IC50分别为 0.24 和 0.3 1μM。MMP-2/MMP-9-IN-1 在肿瘤生长和转移的动物模型中展现出口服活性,可用于研究癌症。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 543 | 现货 | ||
5 mg | ¥ 1,330 | 现货 | ||
10 mg | ¥ 1,990 | 现货 | ||
25 mg | ¥ 3,970 | 现货 | ||
50 mg | ¥ 6,570 | 现货 | ||
100 mg | ¥ 9,870 | 现货 | ||
500 mg | ¥ 19,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,770 | 现货 |
产品描述 | MMP-2/MMP-9-IN-1 is a potent, highly selective and orally bioavailable inhibitor of type IV collagenases (MMP-9 and MMP-2) with an IC50 of 0.24 and 0.3 1 μM for MMP-9 and MMP-2, respectively. activity, which can be used to study cancer. |
靶点活性 | MMP9:0.24 μM, MMP2:0.31 μM |
体外活性 | MMP-2/MMP-9 inhibitor I was identified as a potent inhibitor of matrix metalloproteinase-2 (MMP-2) and MMP-9 with IC50 values of 310 and 240 nM, respectively. MMP-2/MMP-9 inhibitor I acted by binding zinc at the active site of these MMPs. MMP-2/MMP-9 inhibitor I was found to be able to block MMP-2/MMP-9-dependent invasion in cell culture model.[1] |
体内活性 | Both hydroxamic acid and carboxylic acid analogs of MMP-2/MMP-9 inhibitor I were evaluated for their inhibitory activities in animal cancer models. Results showed that lung colonization of Lewis lung carcinoma cells was suppressed by these inhibitors significantly. In addition, antitumor activity was also observed in the human lung cancer model. Ma44 cells growed as a solid tumor on the peritoneum after being implanted ip, and mice bearing Ma44 eventually died within 3 to 4 weeks. Daily oral administration of compound 5l led to prolonged survival of Ma44-bearing mice.[1] |
分子量 | 381.44 |
分子式 | C21H19NO4S |
CAS No. | 193807-58-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 180.0 mg/mL (471.9 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.6216 mL | 13.1082 mL | 26.2164 mL | 65.5411 mL |
5 mM | 0.5243 mL | 2.6216 mL | 5.2433 mL | 13.1082 mL | |
10 mM | 0.2622 mL | 1.3108 mL | 2.6216 mL | 6.5541 mL | |
20 mM | 0.1311 mL | 0.6554 mL | 1.3108 mL | 3.2771 mL | |
50 mM | 0.0524 mL | 0.2622 mL | 0.5243 mL | 1.3108 mL | |
100 mM | 0.0262 mL | 0.1311 mL | 0.2622 mL | 0.6554 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
MMP-2/MMP-9 Inhibitor I 193807-58-8 Proteases/Proteasome MMP MMP 2/MMP 9 Inhibitor I MMP2/MMP9 Inhibitor I Inhibitor inhibitor inhibit